Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

New partnership to advance precision medicine in lung cancer diagnosis

Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in global clinical trials.

Aspyre Lung simplifies the detection of non-small cell lung cancer (NSCLC) biomarkers by analysing both DNA and RNA from tissue and blood using a streamlined four-step workflow.

The partnership aims to support global clinical trials through innovative genomic services. CellCarta will initially set up and validate Aspyre Lung in their European laboratories, followed by their US-based laboratories.

Customers will benefit from revolutionary services using both liquid and tissue biopsy samples. This will help accelerate and facilitate rapid and reliable clinical trial enrolment.

“We are extremely pleased to enter into this strategic partnership with CellCarta,” said Biofidelity Co-Founder and CEO Barnaby Balmforth, PhD. “Partnering with CellCarta to make clinical trial enrolment faster and more efficient utilising Simplified Genomic Profiling (SGP) via Aspyre Lung moves us significantly forward toward fulfilling our mission.”

CellCarta CEO Dusty Tenney expressed excitement about the partnership. “CellCarta offers an extensive portfolio of biomarker testing services and tailored solutions for the pharmaceutical and biotech industry,” he said.

The partnership provides non-exclusive rights to utilise Aspyre Lung for clinical trials globally. This collaboration aims to enhance precision medicine with specialised laboratory services.

Biofidelity’s Aspyre Lung is designed to run on existing qPCR platforms. It integrates seamlessly into laboratories worldwide.

The collaboration underscores the commitment of both companies to advance genomic solutions in precision medicine. It marks a significant step in propelling innovative lung cancer diagnostics.